Serum Human Epidermal Growth Factor 2 Extracellular Domain as a Predictive Biomarker for Lapatinib Treatment Efficacy in Patients With Advanced Breast Cancer [Breast Cancer]

Conclusion
Higher sHER2 predicts greater PFS benefit with lapatinib independent of tHER2 status. High sHER2 is also independently prognostic for worse survival in patients who received nonlapatinib-containing therapies. The predictive role of sHER2 for other anti-HER2 agents requires further research.

Source: Journal of Clinical Oncology - March 9, 2016 Category: Cancer & Oncology Authors: Lee, Davies, Gebski, Lord, Di Leo, Johnston, Geyer, Cameron, Press, Ellis, Loi, Marschner, Simes, de Souza Tags: Translational Oncology, Cancer Biomarkers Breast Cancer Source Type: research